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Background: Previous trials have demonstrated clinically significant and durable reductions in arterial pressure resulting from Baroreflex Activation 
Therapy (BAT). The next-generation Barostim neo System has been designed to deliver BAT with a dramatically simpler device and implant procedure.
Methods: Barostim neo was evaluated in a single-arm, open-label study of patients with resistant hypertension, defined as resting systolic blood 
pressure (SBP) ≥140 mmHg despite treatment with ≥3 medications, including ≥1 diuretic. Stable medical therapy was required for ≥4 weeks prior 
to establishing pre-treatment baseline by averaging 2 SBP readings taken ≥24 hours apart by repeated-measures protocol. Patients with secondary 
hypertension, advanced carotid atherosclerosis, baroreflex failure and severe chronic kidney disease were excluded.
Results: 30 patients were enrolled from 7 centers in Europe and Canada. Three procedure-related complications occurred within 30 days of 
implant, consisting of benign incisional issues. All complications resolved without sequelae. Therapeutic effects at 3 months were comparable to 
previous trials of BAT against a background of stable, intensive medical therapy. 
N = 30 Baseline
(± SD) Δ 3 Months
(± SE, *p < 0.05)
Systolic BP (mmHg) 170.2 ± 20.1 -27.4 ± 3.2*
Diastolic BP (mmHg) 99.5 ± 13.6 -12.5 ± 2.1*
% SBP ≤ 140 mmHg 0% +50%*
Medications 6.1 ± 2.4 -0.2 ± 0.2
Conclusions: BAT delivered by the Barostim neo System significantly lowers blood pressure in resistant hypertension with stable, intensive 
background medical therapy. The safety profile of neo is comparable to a pacemaker.
